Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20 or more at the time when they give consent.~* Diagnosed as malignant disease.~* Be naive to chemotherapy or have been treated with single administration of anti-tumor drugs which are classified as low emetogenicity in the first edition of the 2006 NCCN Clinical Practice Guidelines.~* Cisplatin ≥50 mg/m2 Doxorubicin + cyclophosphamide: AC Epirubicin + cyclophosphamide: EC~* WBC ≥ 3000 /mm3 AST \< 100 IU/L ALT \< 100 IU/L Creatinine clearance ≥ 60 mL/min~* Performance Status : 0 - 2~Exclusion Criteria:~* Severe (requiring hospitalization) and uncontrollable complications.~* Metastases to the brain which are symptomatic.~* Seizure disorder requiring anticonvulsant medication unless clinically stable and free of seizure activity.~* Symptomatic and invasive procedure indicated ascites or pleural effusion.~* Have either gastric outlet stenosis or intestinal obstruction.~* Have ongoing emesis or CTCAE grade 2 or greater nausea.~* QTc \> 470 msec in the 12-lead ECG within eight days before registration.~* Known anaphylactic to ingredients of the study drug, namely palonosetron or granisetron hydrochloride injection, or other 5-HT3 receptor antagonists.~* Known anaphylactic to ingredients of dexamethasone.~* Pregnant women, breast-feeding women, or any male or female who are not willing to practice adequate contraception during the study period.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): palonosetron
- 2 (Type: ACTIVE_COMPARATOR): granisetron hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).